JP2008528532A - 統合失調症のアドオン治療用ｓｐｍ９２７ - Google Patents

統合失調症のアドオン治療用ｓｐｍ９２７ Download PDF

Info

Publication number
JP2008528532A
JP2008528532A JP2007552583A JP2007552583A JP2008528532A JP 2008528532 A JP2008528532 A JP 2008528532A JP 2007552583 A JP2007552583 A JP 2007552583A JP 2007552583 A JP2007552583 A JP 2007552583A JP 2008528532 A JP2008528532 A JP 2008528532A
Authority
JP
Japan
Prior art keywords
use according
unsubstituted
day
alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007552583A
Other languages
English (en)
Japanese (ja)
Inventor
トーマス・シュテール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Pharma GmbH
Original Assignee
UCB Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05001843A external-priority patent/EP1688137A1/en
Application filed by UCB Pharma GmbH filed Critical UCB Pharma GmbH
Publication of JP2008528532A publication Critical patent/JP2008528532A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2007552583A 2005-01-28 2006-01-27 統合失調症のアドオン治療用ｓｐｍ９２７ Withdrawn JP2008528532A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64741005P 2005-01-28 2005-01-28
EP05001843A EP1688137A1 (en) 2005-01-28 2005-01-28 SPM 927 for add-on therapy of schizophrenia
PCT/EP2006/000722 WO2006079547A2 (en) 2005-01-28 2006-01-27 Spm 927 for add-on therapy of schizophrenia

Publications (1)

Publication Number Publication Date
JP2008528532A true JP2008528532A (ja) 2008-07-31

Family

ID=36636204

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007552583A Withdrawn JP2008528532A (ja) 2005-01-28 2006-01-27 統合失調症のアドオン治療用ｓｐｍ９２７

Country Status (12)

Country Link
EP (1) EP1841417A2 (ko)
JP (1) JP2008528532A (ko)
KR (1) KR20070096058A (ko)
AR (1) AR057643A1 (ko)
AU (1) AU2006208630B2 (ko)
BR (1) BRPI0607043A2 (ko)
CA (1) CA2595330A1 (ko)
EA (1) EA015566B1 (ko)
IL (1) IL183973A0 (ko)
MX (1) MX2007009070A (ko)
NO (1) NO20074361L (ko)
WO (1) WO2006079547A2 (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2651679C (en) * 2006-06-15 2017-01-03 Schwarz Pharma Ag Pharmaceutical composition with synergistic anticonvulsant effect
EP1873527A1 (en) 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
EP1920780A1 (en) * 2006-10-12 2008-05-14 Schwarz Pharma Ag Peptide compounds for the treatment of hyperexcitability disorders
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EP2214657A1 (en) 2007-10-23 2010-08-11 UCB Pharma GmbH Compounds for treating demyelination conditions
WO2010077916A1 (en) * 2008-12-16 2010-07-08 Eurand, Inc. Compositions comprising melperone
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
US20130251813A1 (en) 2010-12-02 2013-09-26 Ucb Pharma Gmbh Formulation of lacosamide
CN115813888A (zh) 2016-12-20 2023-03-21 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
AU2017384392B2 (en) 2016-12-20 2023-05-25 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
BR112019027037B1 (pt) 2017-06-26 2022-04-05 Lts Lohmann Therapie-Systeme Ag Sistema terapêutico transdérmico contendo asenapina e polímero híbrido acrílico de silicone, e processo para fabricar uma camada contendo asenapina para uso no referido sistema
CA3088356A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
JP7268026B2 (ja) 2017-12-05 2023-05-02 サノビオン ファーマシューティカルズ インク 非ラセミ混合物およびその使用
CN110958876B (zh) 2018-06-20 2020-12-18 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
CN114401717A (zh) 2019-06-04 2022-04-26 赛诺维信制药公司 修饰释放配制品及其用途
US11278634B1 (en) 2021-02-12 2022-03-22 Extrovis Ag Stable parenteral composition of lacosamide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
DE60120104T2 (de) 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
DE60100055T2 (de) 2001-03-21 2003-07-24 Schwarz Pharma Ag Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen

Also Published As

Publication number Publication date
NO20074361L (no) 2007-10-26
WO2006079547A3 (en) 2006-09-21
WO2006079547A2 (en) 2006-08-03
EA200701594A1 (ru) 2008-02-28
AR057643A1 (es) 2007-12-12
KR20070096058A (ko) 2007-10-01
EA015566B1 (ru) 2011-10-31
MX2007009070A (es) 2007-09-12
AU2006208630A1 (en) 2006-08-03
IL183973A0 (en) 2008-12-29
CA2595330A1 (en) 2006-08-03
EP1841417A2 (en) 2007-10-10
AU2006208630B2 (en) 2011-09-29
BRPI0607043A2 (pt) 2009-08-04

Similar Documents

Publication Publication Date Title
JP2008528532A (ja) 統合失調症のアドオン治療用ｓｐｍ９２７
US20060252749A1 (en) Lacosamide for add-on therapy of psychosis
JP5038892B2 (ja) 本態性振せん及び他の振せん症候群を治療するためのペプチド化合物の新しい使用
JP6158376B2 (ja) 相乗的抗痙攣効果を有する医薬組成物
AU2007260208B2 (en) Peptide compounds for treating refractory status epilepticus
AU2005232395B2 (en) Use of peptidic compounds for the prophylaxis and treatment of chronic headache
JP4938656B2 (ja) ジスキネジアの治療のためのペプチド化合物の新規の使用
US20100324144A1 (en) Therapy for hyperexcitability disorders
ZA200705892B (en) SPM 927 for add-on therapy of schizophrenia
JP4213339B2 (ja) 発作を治療するのに有用なアミノ酸誘導体
RU2508106C2 (ru) Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии
RU2508096C2 (ru) Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081209

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20100205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100205